3E Bioventures Capital — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia VenturesQuan Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital
Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach.
BiotechDeep TechHealthtechMedical Devices
Ying Luo(CEO)in
Co-investorsHongShan Capital Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




